Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum carbonate for hyperphosphataemia in ESRD
NCT00151931Phase 3Completed
- Sponsor
- Takeda
- Start
- May 2004
- Primary completion
- Jan 2006
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of lanthanum carbonate in hyperphosphatemia, sponsored by Takeda. Primary endpoint: Change in pre-dialysis serum phosphate levels at Week 5. Started May 2004; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00151931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151931.